TY - JOUR
T1 - Systematic review of published literature on oxaliplatin and mitomycin C as chemotherapeutic agents for hyperthermic intraperitoneal chemotherapy in patients with peritoneal metastases from colorectal cancer
AU - Wisselink, Daan D.
AU - Braakhuis, Linde L. F.
AU - Gallo, Gaetano
AU - van Grevenstein, Wilhelmina M. U.
AU - van Dieren, S.
AU - Kok, Niels F. M.
AU - de Reuver, Philip R.
AU - Tanis, Pieter J.
AU - de Hingh, Ignace H. J. T.
N1 - Copyright © 2019 Elsevier B.V. All rights reserved.
PY - 2019/10
Y1 - 2019/10
N2 - Background: The role of hyperthermic intraperitoneal chemotherapy (HIPEC) with oxaliplatin in addition to cytoreductive surgery (CRS) has recently been questioned in peritoneal metastases of colorectal cancer. Whether this applies to all published CRS/HIPEC regimens is unclear. Methods: A systematic literature search identified 46 studies on CRS/HIPEC using either oxaliplatin of mitomycin C with at least one oncological outcome parameter Results: Oxaliplatin and mitomycin C studies were comparable regarding extent of disease, but differed substantially regarding synchronous versus metachronous presentation, application of neo-adjuvant systemic chemotherapy, duration of HIPEC, and completeness of cytoreduction for at least one of the oncological endpoints. Severe postoperative complication rate seemed significantly higher after oxaliplatin-based CRS/HIPEC. Conclusion: Published cohorts on oxaliplatin-based CRS/HIPEC differed essentially from MMC-based procedures, especially considering the application of oxaliplatin-containing neo-adjuvant systemic therapy and shorter exposure time to intraperitoneal chemotherapy in oxaliplatin studies. No meaningful comparison could be made regarding DFS and OS.
AB - Background: The role of hyperthermic intraperitoneal chemotherapy (HIPEC) with oxaliplatin in addition to cytoreductive surgery (CRS) has recently been questioned in peritoneal metastases of colorectal cancer. Whether this applies to all published CRS/HIPEC regimens is unclear. Methods: A systematic literature search identified 46 studies on CRS/HIPEC using either oxaliplatin of mitomycin C with at least one oncological outcome parameter Results: Oxaliplatin and mitomycin C studies were comparable regarding extent of disease, but differed substantially regarding synchronous versus metachronous presentation, application of neo-adjuvant systemic chemotherapy, duration of HIPEC, and completeness of cytoreduction for at least one of the oncological endpoints. Severe postoperative complication rate seemed significantly higher after oxaliplatin-based CRS/HIPEC. Conclusion: Published cohorts on oxaliplatin-based CRS/HIPEC differed essentially from MMC-based procedures, especially considering the application of oxaliplatin-containing neo-adjuvant systemic therapy and shorter exposure time to intraperitoneal chemotherapy in oxaliplatin studies. No meaningful comparison could be made regarding DFS and OS.
UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85070191761&origin=inward
UR - https://www.ncbi.nlm.nih.gov/pubmed/31400583
U2 - https://doi.org/10.1016/j.critrevonc.2019.06.014
DO - https://doi.org/10.1016/j.critrevonc.2019.06.014
M3 - Review article
C2 - 31400583
SN - 1040-8428
VL - 142
SP - 119
EP - 129
JO - Critical Reviews in Oncology/Hematology
JF - Critical Reviews in Oncology/Hematology
ER -